Europa Press https://www.europapress.es Europa Press https://s01.europapress.net/imagenes/estaticos/eplogo.gif Europa Press https://www.europapress.es es-ES (C) 2026 Europa Press. Mon, 27 Jul 2026 20:40:33 GMT 60 COMUNICADO: Grünenthal strengthens its Genetic Medicine Capabilities and joins the Cluster for Nucleic Acid Therapeutics https://www.europapress.es/comunicados/salud-0910/noticia-comunicado-grunenthal-strengthens-its-genetic-medicine-capabilities-and-joins-the-cluster-for-nucleic-acid-therapeutics-20260716104909.html (Información remitida por la empresa firmante) - Grünenthal strengthens its Genetic Medicine Capabilities and joins the Cluster for Nucleic Acid Therapeutics Munich NEWS AKTUELL // Aachen, Germany, 16 July 2026 – Grünenthal announced today that the company has joined the Cluster for Nucleic Acid Therapeutics Munich (CNATM), a Munich-centred innovation network that brings together leading universities, research institutions, biotech companies and industry partners to accelerate next-generation nucleic acid therapeutics into innovative treatments that can make a meaningful difference for patients. https://www.europapress.es/comunicados/salud-0910/noticia-comunicado-grunenthal-strengthens-its-genetic-medicine-capabilities-and-joins-the-cluster-for-nucleic-acid-therapeutics-20260716104909.html Thu, 16 Jul 2026 08:49:09 GMT Comunicados Comunicados Salud COMUNICADO: Grünenthal takes full ownership of Grünenthal Med https://www.europapress.es/comunicados/internacional-00907/noticia-comunicado-grunenthal-takes-full-ownership-of-grunenthal-med-20260302104224.html (Información remitida por la empresa firmante) Grünenthal acquired Kyowa Kirin International’s 49% stake in ‘Grünenthal Meds’, a joint venture formed in 2023 to market the established medicines portfolio from Kyowa Kirin International. https://www.europapress.es/comunicados/internacional-00907/noticia-comunicado-grunenthal-takes-full-ownership-of-grunenthal-med-20260302104224.html Mon, 02 Mar 2026 09:42:24 GMT Comunicados Comunicados Internacional COMUNICADO: Grünenthal’s proprietary NaV 1.8 inhibitor enters clinical development https://www.europapress.es/comunicados/internacional-00907/noticia-comunicado-grunenthals-proprietary-nav-18-inhibitor-enters-clinical-development-20260218105350.html (Información remitida por la empresa firmante) Aachen, Germany, 18 February 2026 (News Aktuell)– Grünenthal announced today that the first healthy volunteers have been enrolled in a Phase I trial of its voltage-gated sodium channel (NaV) 1.8 inhibitor. https://www.europapress.es/comunicados/internacional-00907/noticia-comunicado-grunenthals-proprietary-nav-18-inhibitor-enters-clinical-development-20260218105350.html Wed, 18 Feb 2026 09:53:50 GMT Comunicados Comunicados Internacional COMUNICADO: Grünenthal licenses exclusive Canadian rights to testosterone replacement therapy Nebido to Apotex https://www.europapress.es/comunicados/internacional-00907/noticia-comunicado-grunenthal-licenses-exclusive-canadian-rights-to-testosterone-replacement-therapy-nebido-to-apotex-20260205154719.html (Información remitida por la empresa firmante) Aachen, Germany & Toronto, Canada, February 5, 2026 (News Aktuell) – Grünenthal, a global leader in pain management and related diseases, and Apotex Inc. https://www.europapress.es/comunicados/internacional-00907/noticia-comunicado-grunenthal-licenses-exclusive-canadian-rights-to-testosterone-replacement-therapy-nebido-to-apotex-20260205154719.html Thu, 05 Feb 2026 14:47:19 GMT Comunicados Comunicados Internacional